BACKGROUND: Atypical antipsychotics have been assessed for normalization effects on deficient sensory gating as indexed by prepulse inhibition (PPI) in schizophrenics with generally positive, although somewhat conflicting, results. METHODS: We tested the acute effect of clozapine on startle, PPI, and attention, working memory, and executive functioning in 28 healthy male volunteers with low versus high PPI levels using a placebo-controlled within-subject design. RESULTS:Clozapine significantly increased PPI levels obtained at short lead intervals of 60 and 120 msec in subjects with low PPI performance but showed no effect in subjects with high PPI. Clozapine also caused a mild cognitive impairment on attention and pattern recognition memory tests. No correlations between cognitive measures and PPI performance were found. Moreover, low and high PPI performers were shown to exhibit stable levels of PPI across three separate nondrug testing days. CONCLUSIONS:Clozapine increases sensorimotor gating in healthy subjects with low but not high PPI levels in a manner comparable to that seen in clozapine-treated schizophrenia patients. Healthy subjects with low PPI level in combination with genetic studies may provide a translational model to elucidate the neuronal basis of PPI deficits and to test the efficacy of novel antipsychotic medication.
RCT Entities:
BACKGROUND: Atypical antipsychotics have been assessed for normalization effects on deficient sensory gating as indexed by prepulse inhibition (PPI) in schizophrenics with generally positive, although somewhat conflicting, results. METHODS: We tested the acute effect of clozapine on startle, PPI, and attention, working memory, and executive functioning in 28 healthy male volunteers with low versus high PPI levels using a placebo-controlled within-subject design. RESULTS:Clozapine significantly increased PPI levels obtained at short lead intervals of 60 and 120 msec in subjects with low PPI performance but showed no effect in subjects with high PPI. Clozapine also caused a mild cognitive impairment on attention and pattern recognition memory tests. No correlations between cognitive measures and PPI performance were found. Moreover, low and high PPI performers were shown to exhibit stable levels of PPI across three separate nondrug testing days. CONCLUSIONS:Clozapine increases sensorimotor gating in healthy subjects with low but not high PPI levels in a manner comparable to that seen in clozapine-treated schizophreniapatients. Healthy subjects with low PPI level in combination with genetic studies may provide a translational model to elucidate the neuronal basis of PPI deficits and to test the efficacy of novel antipsychotic medication.
Authors: Alan E Ceaser; Terry E Goldberg; Michael F Egan; Robert P McMahon; Daniel R Weinberger; James M Gold Journal: Biol Psychiatry Date: 2008-07-02 Impact factor: 13.382
Authors: Philipp A Csomor; Katrin H Preller; Mark A Geyer; Erich Studerus; Theodor Huber; Franz X Vollenweider Journal: Neuropsychopharmacology Date: 2014-05-07 Impact factor: 7.853
Authors: José A Larrauri; Lisalynn D Kelley; Mason R Jenkins; Eric C Westman; Nestor A Schmajuk; M Zachary Rosenthal; Edward D Levin Journal: Neuropsychopharmacology Date: 2013-09-18 Impact factor: 7.853
Authors: Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff Journal: Psychopharmacology (Berl) Date: 2008-06-21 Impact factor: 4.530
Authors: S de la Salle; D Smith; J Choueiry; D Impey; T Philippe; H Dort; A Millar; P Albert; V Knott Journal: Neuroscience Date: 2013-03-25 Impact factor: 3.590
Authors: Neal R Swerdlow; Sophia A Lelham; Ashley N Sutherland Owens; Wei-Li Chang; Sebastiaan D T Sassen; Jo A Talledo Journal: Psychopharmacology (Berl) Date: 2009-06-09 Impact factor: 4.530